Tyrosinase activated melanoma prodrugs

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 7, 2009, Pages 717-727

  Jawaid, Samaila ^a   Khan, Tariq H ^a   Osborn, Helen M I ^a   Williams, Nana Aba O ^b  

^a UNIVERSITY OF READING   (United Kingdom)

^b Novartis Oncology   (Spain)

Author keywords

Melanogenesis; Melanoma; Metastasis; Ortho; Prodrug; Tyrosinase

Indexed keywords

2,4 DIHYDROXYPHENYLALANINE; 4 AMINOPHENOL; 4 S CYSTEAMINYLPHENOL; 6 AMINODOPAMINE DERIVATIVE; ALPHA INTERFERON; CARBIDOPA; CARMUSTINE; DACARBAZINE; DOPAMINE; DOPAMINE DERIVATIVE; IMIQUIMOD; INTERLEUKIN 2; LEVODOPA; LOMUSTINE; MELANIN; MELPHALAN; MEQUINOL; MONOPHENOL MONOOXYGENASE; N ACETYL 4 S CYSTEAMINYLPHENOL; N PROPIONYL 4 S CYSTEAMINYLPHENOL; OBLIMERSEN; PHENOL DERIVATIVE; TEMOZOLOMIDE; TYROSINE; UNCLASSIFIED DRUG;

ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW DEPRESSION; BONE MARROW TOXICITY; CARCINOGENESIS; CHEMICAL MODIFICATION; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG CYTOTOXICITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; EARLY DIAGNOSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PRODRUG THERAPY; ENZYME REGULATION; ENZYMOLOGY; FATIGUE; GENOTYPE ENVIRONMENT INTERACTION; HORMONE SYNTHESIS; HUMAN; KIDNEY INJURY; LUNG TOXICITY; MALIGNANT TRANSFORMATION; MELANOGENESIS; MELANOMA; MULTIPLE MYELOMA; MUSCLE ATROPHY; NAUSEA; NAUSEA AND VOMITING; NEUTRON CAPTURE THERAPY; NONHUMAN; REACTION ANALYSIS; REVIEW; SEIZURE; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTINEOPLASTIC AGENTS; HUMANS; MELANINS; MELANOMA; MONOPHENOL MONOOXYGENASE; PRODRUGS;

EID: 73449090098     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009789056886     Document Type: Review

References (99)

1. i. http://www.melanoma.com;
2. ii. http://www.cancer.gov/ cancertopics/ types/melanoma;
3. iii. http://www.skincancer.org/melanoma/
4. For reviews on the treatment of metastatic malignant melanoma see i. Atallah, E.; Flaherty, L. Treatment of metastatic malignant melanoma. Curr. Treat. Options Oncol., 2005, 6, 185;
5. ii. Martinez, S.R.; Young, S.E. A rational surgical approach to the treatment of distant melanoma metastases. Cancer Treat. Rev., 2008, 34, 1093;
6. iii. Awada, A.; Piccart, M. Strategies offering protection from the toxic effects of anticancer treatments with a focus on chemoprotective agents. Curr. Opin. Oncol., 2000, 12, 289;
7. iv. Namkoong, J.; Martino, J.J.; Chen. S. From existing therapies to novel targets: a current view on melanoma. Front. Biosci, 2006, 11, 2081.
8. Goldstein, A. M.; Tucker, M. A. Genetic epidemiology of cutaneous melanoma - A global perspective. Arch. Dermatol., 2001, 137, 1493.
9. www.myriadtests.com
10. i. Lund, L.P.; Timmins, G.S. Melanoma, long wavelength ultraviolet and sunscreens: Controversies and potential resolutions. Pharmacol. Ther., 2007, 114, 198;
11. ii. Marks, R. Epidemiology of melanoma. Clin. Exp. Dermatol., 2000, 25, 459.
12. Uyen, L.D.P.; Nguyen, D.H.; Kim, E.K. Mechanism of skin pigmentation. Biotech. Bioprocess. Eng., 2008, 13, 383.
13. i. Ito, Y.; Jimbow, K. Selective cytotoxicity of 4-S-cysteaminylphenol on follicular melanocytes of the black mouse - rational basis for its application to melanoma chemotherapy. Cancer Res., 1987, 47, 3278;
14. ii. Prota, G.; d'Ischia, M.; Mascagna, D. Melano-genesis as a targeting strategy against metastatic melanoma - a reassessment. Melanoma Res., 1994, 4, 351.
15. i. Hearing, V. J.; Lutzner, M. A. Mammalian melanosomal proteins: characterization by polycrylamide gel electrophoresis. J. Bio. Med., 1973, 46, 553;
16. ii. Riley, P. A. Melanin. Int. J. Biochem. Cell Biol., 1997, 11, 1235.
17. Hearing, V. J. Mammalian monophenol monooxygenase (tyrosinase): purification , properties, and reactions catalyzed. Methods Enzymol., 1987, 1142, 154.
18. Riley, P. A. Melanogenesis and melanoma. Pigment Cell Res., 2003, 16, 548.
19. i. Pawelek, J.; Korner, A.; Bergstrom, A.; Bologna, J. New regulators of melanin biosynthesis and the auto-destruction of melanma cells. Nature, 1980, 286, 617;
20. ii. Riley, P. A. Melanogenesis - a realistic target for antimelanoma therapy. Eur. J. Cancer, 1991, 27, 1172.
21. Land, E. J.; Ito, S.; Wakamatsu, K.; Riley, P. A. Rate constants for the first two chemical steps of eumelanogenesis. Pigment Cell Res., 2003, 16, 487.
22. Chedekel, M. R.; Land, E. J.; Thompson, A.; Truscott, T. G. Early steps in the free radical polymerisation of 3,4-dihydroxy-phenylalanine (Dopa) into melanin. J. Chem. Soc. Chem. Commun., 1984, 1170.
23. Smit, N. P. M.; Pavel, S.; Riley, P. A. In Mechanisms of Control of the Cytotoxicity of Orthoquinone Intermediates of Melanogenesis. Creveling, C. R., Ed. Role of Catechol Quinone Species in Cellular Toxicity. Johnson City: FP Graham Publishing: 1999, pp.191-245.
24. Land, E. J.; Ramsden, C. A.; Riley, P. A. Quinone chemistry and melanogenesis. Methods Enzymol., 2004, 378, 88.
25. Pawelek, J.; Korner, A.; Bergstrom, A.; Bologna, J. New regulators of melanin biosynthesis and the autodestruction of melanoma cells. Nature, 1980, 286, 617.
26. Ancans, J.; Tobin, D. J.; Hoogdujin, M.J.; Smit, N. P.; Wakamatsu, K.; Thody, A. J. Melanosomal pH controls rate of melanogenesis, eumelanin/ phaeomelanin ratio and melanosome maturation in melanocytes and melanoma cells. Exp. Cell Res., 2001, 268, 26.
27. Martinez, J. H.; Solano, F.; Penafiel, R.; Lozano, A. Half-lives of tyrosinase isozymes from Harding-Passey mouse melanoma. Cancer Lett., 1988, 38, 339.
28. Jara, J. R.; Solano, F.; Lozano, J. A. Assays for mammalian tyrosinase: a comparative study. Pigment Cell Res., 1988, 1, 332.
29. i. Van Holde, K. E.; Miller, K. I.; Decker, H. Hemocyanins and invertebrate evolution. J. Biol. Chem., 2001, 276, 15563;
30. ii. Naish-Byfield, S.; Riley, P. A. Tyrosinase autoactivation and the problem of the lag period. Pigment Cell Res., 1998, 11, 127;
31. iii. Land, E. J.; Ramsden, C. A.; Riley, P. A. Tyrosinase autoactivation and the chemistry of ortho-quinone amines. Acc. Chem. Res., 2003, 36, 300.
32. Seiji, M.; Yoshida, T.; Itakura, H.; Toshikatsu, I. Inhibition of melanin formation by sulfhydryl compounds. J. Invest. Dermatol. 1969, 52, 280.
33. Del Marmol, V.; Solano, F.; Sels, A.; Huez, G.; Libert, A.; Lejeune, F.; Ghanem, G. Glutathione depletion increases tyrosinase activity in human melanoma cells. J. Invest. Dermatol., 1993, 101, 871.
34. Jara, J. R.; Aroca, P.; Solano, F.; Martinez, J. H.; Lozano, J. A. The role of sulfhydryl compounds in mammalian melanogenesis: the effect of cysteine and glutathione upon tyrosinase and the intermediates of the pathway. Biochim. Biophys. Acta, 1988, 967, 296.
35. Jergil, B.; Lindbladh, C. H.; Rorsman, H.; Rosengren, E. Inactivation of human tyrosinase by cysteine. Protection by dopa and tyrosine. Acta Dermatol. Venereol., 1984, 64, 155.
36. Mota, A.; Deisseroth, A. Systemic treatment of malignant melanoma. Clin. Plast. Surg., 2000, 27, 463.
37. Komenaka, I.; Hoerig, H.; Kaufman, H. L. Immunotherapy for melanoma. Clin. Dermatol., 2003, 22, 251.
38. Zarour, H. M.; Kirkwood, J. M. Melanoma vaccines: early progress and future promises. Semin. Cutan. Med. Surg., 2003, 22, 68.
39. Martinez, S.R.; Young, S.E. A rational surgical approach to the treatment of distant melanoma metastases. Cancer Treat. Rev., 2008, 34, 1093.
40. Dietrich, S.; Kasper, B. Targeted therapeutic strategies in malignant melanoma. Drug Discov. Today: Dis. Mech., 2008, 5, e63.
41. Ray, C. M.; Kluk, M.; Grin, C. M.; Grant-Kels, J. M. Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. Int. J. Dermatol., 2005, 44, 428.
42. Hocker, T.L.; Singh, M.K.; Tsao, H. Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J. Invest. Dermatol., 2008, 128, 2575
43. Morgan R. A., Dudley M. E., Wunderlich J. R., Hughes M. S., Yang J. C., Sherry R. M., Royal R. E., Topalian S. L., Kammula U. S., Restifo N. P., Zheng Z., Nahvi A., de Vries C. R., Rogers-Freezer L. J., Mavroukakis S. A., Rosenberg S. A. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 2006, 314, 126.
44. i. Jansen, B.; Wacheck, V.; Heere-Ress, E.; Schlagbauer-Wadl, H.; Hoeller, C.; Lucas, T.; Hoermann, M.; Hollenstein, U.; Wolff, K.; Pehamberger. H. Chemosensitization of malignant melanoma by Bcl-2 antisense therapy. Lancet, 2000, 356, 1728;
45. ii. Eberle, J.; Hossini, A.M. Expression and function of Bcl-2 proteins in melanoma. Curr. Genomics, 2008, 9, 409.
46. i. Altaner C. Prodrug cancer gene therapy. Cancer Lett., 2008, 270, 191;
47. ii. Chin, L.; Garraway, L.A.; Fisher, D.E. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev., 2006, 20, 2149.
48. i. Eigentler, T. K.; Caroli, U. M.; Radny, P.; Garbe, C. Palliative therapy of disseminated malignant melanoma: A systematic review of 41 randomised clinical trials. Lancet Oncol., 2003, 4, 748;
49. ii. Verma, S.; Petrella, T.; Hamm, C.; Bak, K.; Charette, M. Biochemotherapy for the treatment of metastatic malignant melanoma: a clinical practice guideline. Curr. Oncol., 2008, 15, 85;
50. iii. Hamm, C.; Verma, S.; Petrella, T.; Bak, K.; Charette, M. Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review. Cancer Treat. Rev., 2008, 34, 145.
51. Quirt, I.; Verma, S.; Petrella, T.; Bak, K.; Charette, M. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist, 2007, 12, 1114.
52. Quirt I.; Verma S.; Petrella T.; Bak K.; Charette M. Temozolomide for the Treatment of Metastatic Melanoma: A Clinical Practice Guideline, Cancer Care Ontario (CCO): Toronto, 2006, p. 25.
53. nd ed.), Oxford University Press, 1994.
54. Lens, M. B.; Eisen, T.G. Systemic chemotherapy in the treatment of malignant melanoma Expt. Opin. Pharmacother., 2003, 12, 2205.
55. Nathan, F. E.; Mastrangelo, M. J. Systemic therapy in melanoma. Semin. Surg. Oncol., 1998, 14, 319.
56. i. Rooseboom, M.; Commandeur, J.N.M.; Vermeulen, N.P.E. Enzyme-Catalyzed activation of anticancer prodrugs. Pharmacol. Rev., 2004, 56, 53;
57. ii. Singh, Y.; Palombo, M.; Sinko, P.J. Recent trends in targeted anticancer prodrug and conjugate design. Curr. Med. Chem., 2008, 15, 1802;
58. iii. Kratz, F.; Muller, I.A.; Ryppa, C.; Warnecke, A. Prodrug strategies in anticancer chemotherapy. Chem. Med. Chem., 2008, 3, 20.
59. Riley, P. A. Melanogenesis and melanoma. Pigment Cell Res., 2003, 16, 548.
60. Naish-Byfield, S.; Cooksey, C. J.; Latter, A. M.; Johnson, C. I.; Riley, P. A. In vitro assessment of the structure - activity relationship of tyrosinase-dependent cytotoxicity of a series of substituted phenols. Melanoma Res., 1991, 1, 273.
61. i. Cooksey, C. J.; Jimbow, J.; Land, E. J.; Riley, P. A. Reactivity of orthoquinones involved in tyrosinase-dependent cytotoxicity: differences between alkylthio- and alkoxy-substituents. Melanoma Res., 1992, 2, 283;
62. ii. Cooksey, C. J.; Land, E. J.; Ramsden, C. A.; Riley, P. A. Tyrosinase mediated cytotoxicity of 4-substituted phenols: quantitative structure-thiol-reactivity relationship of the derived o-quinones. Anti-Cancer Drug Des., 1995, 10, 119;
63. iii. Cooksey, C. J.; Land, E. J.; Rushton, F. A. P.; Ramsden, C. A.; Riley, P. A. Tyrosinase-mediated cytotoxicity of 4-substituted phenols: use of QSAR to forecast reactivities of thiols towards the derived ortho-quinones. Quant. Struct. - Act Relat., 1996, 15, 498.
64. Riley, P. A. Mechanism of pigment-cell toxicity produced by hydroxyanisole. J. Pathol., 1970, 101, 163.
65. Wick, M. M. An experimental approach to the chemotherapy of melanoma. J. Invest Dermatol., 1980, 74, 63.
66. Jimbow, K.; Iwashina, T.; Alena, F.; Yamada, K.; Pankovich, J.; Umemura, T. Exploitation of pigment biosynthesis pathway as a selective chemotherapeutic approach for mlaginant melanoma. J. Invest. Dermatol., 1993, 100, 231S.
67. i. Riley, P. A. Hydroxyanisole; Recent Advances in Antimelanoma Therapy, IRL Press: Oxford, 1984,
68. ii. Riley, P. A.; Cooksey, C. J.; Johnson, C.I.; Land, E. J.; Latter, A. M.; Ramsden, C. A. Melano-genesis-targeted anti-melanoma pro-drug development: Effect of side-chain variations on the cytotoxicity of tyrosinase-generated ortho-quinones in a model screening system. Eur. J. Cancer, 1997, 33, 135.
69. Smit, N. P. M.; Peters, K. Menko, W.; Westerhof, W.; Pavel, S.; Riley, P. A. Cytotoxicity of a selected series of substituted phenols towards cultured melanoma cells. Melanoma Res., 1992, 2, 295.
70. Moridani, M. Y. Biochemical basis of 4-hydroxyanisole induced cell toxicity towards B16-F0 melanoma cells. Cancer Lett., 2006, 243, 235.
71. Morgan, B. D. G. In Hydroxyanisole: Recent Advances in Anti-Melanoma Therapy, P. A. Riley, Ed.; IRL Press: England, 1984, pp. 233-241.
72. Morrison, M. E.; Yagi, M. J.; Cohen, G. In vitro studies of 2,4-dihydroxyphenylalanine, a prodrug targeted against malignant melanoma cells. Proc. Natl. Acad. Sci. USA, 1985, 82, 2960.
73. Rodriguez-Lopez, J. N.; Banon Arnao, M.; Martinez-Ortiz, F.; Tudela, J.; Acosta, M.; Varon, R.; Garcia-Carnovas, F. Catalytic oxidation of 2,4,5-thihydroxyphenylalanine by tyrosinase: identification and evolution of intermediates. Biochim. BioPhys. Acta, 1992, 1160, 221.
74. i. Ito, S.; Kato, T.; Ishikawa, K.; Kasuya, T.; Jimbow, K. Dihydro-1,4-benzothiazine-6,7-dione, the ultimate toxic metabolite of 4-S-Cysteaminylphenol and 4-S-Cysteaminylcatechol. Biochem. Pharmacol., 1987, 36, 2007;
75. ii. Inoue, S.; Hasegawa, K.; Ito, S.; Ozeki, H.; Solano, F.; Jimenez-Cervantes, C. Antimelanoma effect of 4-Scysteaminylcatechol, an activated form of 4-S-cysteaminyl-phenol. Cancer Res., 1995, 55, 2603.
76. i. Jimbow, K.; Iwashina, T.; Alena, F.; Yamada, K.; Pankovich, J.; Umemura, T. Exploitation of pigment biosynthesis pathway as a selective chemotherapeutic approach for malignant melanoma. J. Invest. Dermatol., 1993, 100, 231S;
77. ii. Gili, A.; Thomas, P. D.; Ota, M.; Jimbow, K. Comparison of in vitro cytotoxicity of N-acetyl and N-propionyl derivatives of phenolic thioether amines in melanoma and neuroblastoma cells and the relationship to tyrosinase and tyrosine hydroxylase enzyme activity. Melanoma Res., 2000, 10, 9;
78. iii. Pearson, V. C.; Ferguson, J.; Royers, P. M.; Kelland, L. R.; Robins, D. J. Synthesis and antimelanoma activity of tertiary amide analogues of N-acetyl-4-S-cysteaminylphenol. Oncol. Res., 2003, 13, 503.
79. Simonova, M.; Wall, A.; Weissleder, R.; Bogdanov Jr., A. Tyrosinase mutants are capable of prodrug activation in transfected nonmelanotic cells. Cancer Res., 2000, 60, 6656.
80. Ito, A.; Fujioka, M.; Yoshida, T.; Wakamatsu, K.; Ito, S.; Yamashita, T.; Jimbow, K.; Honda, H. 4-S-Cysteaminylphenol-loaded magnetite cationic liposomes for combination therapy of hyperthermia with chemotherapy against malignant melanoma. Cancer Sci. 2007, 98, 424.
81. i. Jordan, A. M.; Khan, T. H.; Osborn, H. M. I.; Photiou, A.; Riley, P. A. Melanocyte-directed enzyme prodrug therapy (MDEPT): Development of a targeted treatment for malignant melanoma. Bioorg. Med. Chem., 1999, 7, 1775;
82. ii. Jordan, A. M.; Khan, T. H.; Malkin, H.; Osborn, H. M. I.; Photiou, A.; Riley, P. A. Melanocyte-Directed Enzyme Prodrug Therapy (MDEPT): Development of second generation prodrugs for targeted treatment of malignant melanoma. Bioorg. Med. Chem., 2001, 9, 1549;
83. iii. Jordan, A. M.; Khan, T. H.; Malkin, H.; Osborn, H. M. I. Synthesis and analysis of urea and carbamate prodrugs as candidates for melanocyte-directed enzyme prodrug therapy (MDEPT). Bioorg. Med. Chem., 2002, 10, 2625.
84. i) Seo, S. Y.; Sharma, V. K.; Sharma, N. Mushroom tyrosinase: Recent prospects. J. Agric. Food. Chem., 2003, 51, 2837;
85. ii) Müller, G. H.; Land, A.; Seithel, D. R.; Waldmann, H. An enzyme-initiated hydroxylation-oxidation carbo diels-alder domino reaction. Chem-Eur. J., 1998, 4, 2513.
86. iii) Schoot-Uiterkamp, A. J. M.; Mason, H. S. Magnetic dipole-dipole coupled Cu(II) pairs in nitric oxide-treated tyrosinase: a structural relationship between the active sites of tyrosinase and hemocyanin. Proc. Natl. Acad. Sci. USA, 1973, 70, 993.
87. Knaggs, S.; Malkin, H.; Osborn, H.M.I.; Williams, N.A.O.; Yaqoob, P. New prodrugs derived from 6-aminodopamine and 4-aminophenol as candidates for Melanocyte-Directed Enzyme Prodrug Therapy (MDEPT). Org. Biomol. Chem., 2005, 3, 4002.
88. Borovansky, J.; Edge, R.; Land, E. J.; Navaratnam, S.; Pavel, S.; Ramsden, C. A.; Riley, P. A.; Smit, N. P. M. Mechanistic studies of melanogenesis: the influence of N-substitution on dopamine quinone cyclization. Pigment Cell Res., 2006, 19, 170.
89. Gasowska-Bajger, B.; Wojtasek, H. Indirect oxidation of the anti-tumor agent procarbazine by tyrosinase--possible application in designing anti-melanoma prodrugs. Bioorg. Med. Chem. Lett., 2008, 18, 3296.
90. Smit, N. P. M.; Van der Meulen, H.; Koerten, H. K.; Kolb, R. M.; Mommaas, A. M.; Lentjes, E. G. W. M.; Pavel, S. Melanogenesis in cultured melanocytes can be substantially influenced by l-tyrosine and l-cysteine. J. Invest. Dermatol., 1997, 109, 796.
91. Pawlek, J. M.; Wong, G.; Sansone, M.; Marowitz, J. Molecular controls in mammalian pigmentation. J. Biol. Med., 1973, 46, 430.
92. Wick, M.; Frei, E. Selective incorporation of l-3,4-dihydroxy- phenylalanine by S-91 cloudman melanoma in vitro. Cancer Res., 1977, 37, 2123.
93. Berjian, R.A.; Kanter, P.M.; Bhakoo, H.S.; Tan, M.H.; Lawrence, D.D. Pretreatment effects on the uptake / retention kinetics of L-Dopa in harding-passey melanoma, J. Invest. Dermatol., 1986, 86, 560.
94. Wick, M. Dopamine: A novel antitumor agent active against B-16 melanoma in vivo. J. Invest. Dermatol., 1978, 71, 163.
95. Wick, M. Therapeutic effects of dopamine infusion on human malignant melanoma. Cancer Treat. Rep., 1982, 66, 1657.
96. Wick, M. L-Dopa methyl ester: prolongation of survival of neuroblastoma-bearing mice after treatment. Science, 1978, 199, 775.
97. Wick, M.M.; Byers, L.; Frei 3rd, E. L-Dopa: selective toxicity for melanoma cells in vitro. Science, 1977, 197, 468.
98. Bonjoch, J.; Drew, M.G.B.; Gonzalez, A.; Greco, F.; Jawaid, S.; Osborn, H.M.I.; Williams, N.A.O.; Yaqoob, P. Synthesis and Evaluation of novel boron-containing complexes of potential use for the selective treatment of malignant melanoma. J. Med. Chem., 2008, 51, 6604.
99. Barth, R.F. Boron neutron capture therapy of cancer: current status and future prospects. Clin. Cancer Res., 2005, 11, 3987-4002.